Analyzing...
Loading company...
Aurobindo Pharma Ltd. engages in the manufacturing of generic pharmaceuticals and active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana and currently employs 15,690 full-time employees. The firm develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients. Its product portfolio is spread over seven therapeutic/product areas encompassing central nervous systems (CNS), anti-retroviral, cardiovascular (CVS), antibiotics, gastroenterological, anti-diabetics and anti-allergic. The company is engaged in developing a range of oncology and hormonal products. The company is developing topical as well as transdermal products in the dermatology therapeutic segment. The company is also developing about three depot injections based on the microsphere and nano-suspension technology platforms. The firm is marketing its products globally in approximately 150 countries. The firm's subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited and Aurolife Pharma LLC, among others.
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹33,653 Cr revenue.
COGS 40.1%, employees 15.4%.
“We are confident of achieving our internal margin target of 20 to 21% for FY26 as communicated earlier”
“Consolidated revenues grew by 6% year on year to 8,286 crores. EBITDA 1,678 crore with margin of 20.3%, demonstrating 7% year on year growth”
“European business delivered 18% year on year revenue growth to 2,480 crores (243M euros). Firmly on track to surpass 1 billion annual revenue milestone by end of FY26”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 9.3%▼ | 10.3% |
| ROCE | 13.6%▼ | 13.7% |
| Net Margin | 10.3%▲ | 7.6% |
| EBITDA Margin | 21.3%▲ | 15.4% |
| Debt To Equity | 0.20x▲ | 0.15x |
| Rev Growth 3yr | 10.7%▲ | 10.0% |
| EPS Growth 3yr | 22.4%▲ | 16.0% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹33,653 Cr +6.1% | ₹31,724 Cr +9.4% | ₹29,002 Cr +16.7% | ₹24,855 Cr +6.0% | ₹23,455 Cr -5.3% | ₹24,775 Cr +7.3% | ₹23,099 Cr +18.1% | ₹19,564 Cr |
| Other Income | ₹531 Cr -14.7% | ₹622 Cr +11.6% | ₹557 Cr +91.8% | ₹291 Cr -9.3% | ₹320 Cr -15.9% | ₹381 Cr +341.8% | ₹86 Cr -25.5% | ₹116 Cr |
| Total Income | ₹34,184 Cr +5.7% | ₹32,346 Cr +9.4% | ₹29,559 Cr +17.6% | ₹25,146 Cr +5.8% | ₹23,776 Cr -5.5% | ₹25,155 Cr +8.5% | ₹23,185 Cr +17.8% | ₹19,679 Cr |
| COGS | ₹13,488 Cr +3.5% | ₹13,026 Cr +3.4% | ₹12,603 Cr +11.6% | ₹11,293 Cr +11.4% | ₹10,140 Cr +2.4% | ₹9,902 Cr +1.7% | ₹9,735 Cr +11.7% | ₹8,713 Cr |
| ₹29,008 Cr +6.5% | ₹27,248 Cr +9.1% | ₹24,970 Cr +10.9% | ₹22,522 Cr +11.3% | ₹20,244 Cr -1.6% | ₹20,571 Cr +6.0% | ₹19,400 Cr +17.6% | ₹16,503 Cr | |
| Profit Before Tax | ₹5,110 Cr +0.2% | ₹5,098 Cr +15.9% | ₹4,397 Cr +67.6% | ₹2,624 Cr -22.9% | ₹3,404 Cr -54.0% | ₹7,399 Cr +96.9% | ₹3,758 Cr +21.7% | ₹3,089 Cr |
| Exceptional Items | (₹65 Cr) | ₹0.00 Cr +100.0% | (₹192 Cr) | ₹0.00 Cr +100.0% | (₹128 Cr) ↓ Decline | ₹2,815 Cr ↑ Recovery | (₹26 Cr) +70.3% | (₹88 Cr) |
| ₹1,609 Cr +1.7% | ₹1,583 Cr +30.7% | ₹1,211 Cr +76.8% | ₹685 Cr -5.6% | ₹726 Cr -63.9% | ₹2,010 Cr +120.0% | ₹914 Cr +25.7% | ₹727 Cr | |
| Net Profit | ₹3,503 Cr +0.6% | ₹3,484 Cr +9.9% | ₹3,169 Cr +64.4% | ₹1,928 Cr -27.2% | ₹2,647 Cr -50.4% | ₹5,334 Cr +88.5% | ₹2,830 Cr +19.7% | ₹2,365 Cr |
| Profit (Owners) | ₹3,505 Cr +0.5% | ₹3,486 Cr +9.9% | ₹3,173 Cr +64.6% | ₹1,928 Cr -27.2% | ₹2,648 Cr -50.4% | ₹5,335 Cr +88.4% | ₹2,831 Cr +19.7% | ₹2,365 Cr |
| Minority Interest | (₹2 Cr) +22.9% | (₹2 Cr) +42.3% | (₹4 Cr) ↓ Decline | ₹0.15 Cr ↑ Recovery | (₹1 Cr) -2.0% | (₹1 Cr) +30.1% | (₹1 Cr) -534.8% | (₹0.23 Cr) |
| Other Comprehensive Income | ₹1,965 Cr +547.3% | ₹304 Cr +206.2% | ₹99 Cr -86.5% | ₹736 Cr +181.1% | ₹262 Cr | ₹5 Cr -98.3% | ₹287 Cr ↑ Recovery | (₹4 Cr) |
| EPS | ₹60.34 | ₹60.02 | ₹54.15 | ₹32.90 | ₹45.20 | ₹91.05 | ₹48.32 | ₹40.36 |
| Diluted Shares | ₹58 Cr | ₹58 Cr | ₹59 Cr | ₹59 Cr | ₹59 Cr | ₹59 Cr | ₹59 Cr | ₹59 Cr |
| Profit Or Loss Of Associates | ₹2 Cr ↑ Recovery | (₹32 Cr) -84.7% | (₹17 Cr) -47.0% | (₹12 Cr) +62.7% | (₹31 Cr) +43.6% | (₹55 Cr) -264.9% | (₹15 Cr) ↓ Decline | ₹3 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Aurobindo Pharma Limited has informed the Exchange about Copy of Newspaper Publication
Aurobindo Pharma Limited has iIntimated the date of 39th Annual General Meeting of Aurobindo Pharma Limited.
Aurobindo Pharma Limited has informed the Exchange about schedule of Earnings Call to be held on August 6, 2026 at 8:30 AM (IST) on Unaudited Financial Results of the Company for the first quarter end...
Aurobindo Pharma Limited has informed the Exchange regarding a press release dated July 24, 2026, titled "Aurobindo Pharma signs non-exclusive voluntary license agreement with MSD".
Aurobindo Pharma Limited has informed the Acquisition of majority ownership control in A1 Biochem Labs (India) Private Limited, India and A1 Biochem Labs LLC, USA .
Intimation of receipt of ANVISA Approval for Biosimilars Manufacturing Facility of CuraTeQ Biologics Private Limited, a wholly owned subsidiary of the Company.
Aurobindo Pharma Limited has informed the Exchange about incorporation of a new wholly owned stepdown subsidiary in Indonesia.
Intimation of completion of Lannett acquisition by Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company.
Aurobindo Pharma Limited has informed the Exchange about Completion of US FDA Inspection at Auroactive Pharma Private Limited, a wholly owned subsidiary of the Company.
Aurobindo Pharma Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regul...
Aurobindo Pharma Limited has informed that the necessary approval from US Federal Trade Commission (FTC) for the acquisition of the Lannett business has been obtained today.
Aurobindo Pharma Limited has informed the Exchange about Copy of Newspaper Publication
Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
Aurobindo Pharma Limited has informed the Exchange about Schedule of investor meeting.